Category

News Brief

Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030

UF Startup Kate Therapeutics, a gene therapy specialist, is being acquired by Novartis in a deal worth up to $1.1 billion. This acquisition aligns with Novartis’s efforts to deliver treatments for neuromuscular disorders and fits into the pharma’s strategy to expand its new modality pipeline, ensuring long-term business sustainability.